Stig Løkke Pedersen holds a Masters in Economy from Aalborg University and currently serves as the chairman of the Board for the 4 biotech and life science tools companies in Europe and North America. For 20 years Stig served as an executive in the Danish pharmaceutical company H. Lundbeck A/S, most recently as Executive Vice President of Commercial Operations. Stig also is a partner in Executive Capital and an advisor to the Lundbeck Foundation, JSB partners and Atrium partners.
Morten Sommer, M.Sc., PhD, is the developer of the technology and the founder of Microlytic, LLC. He has been working on microfluidic devices for protein crystallization over the past decade at Microlytic, the California Institute for Technology and the University of Copenhagen. He is the inventor on over 10 patents and patent applications within the field of microfluidics and protein crystallization. At California Institute of Technology he co-invented the use of multi-layer soft lithography devices for protein crystallization. He co-developed the use of microfluidic formulators for experimental mapping of protein phase diagrams enabling targeted and rational approaches to protein crystallization Subsequently Morten developed injection molded microfluidic technology for liquid-liquid diffusion based crystallization which led to the Crystal Former and the formation of Microlytic which he founded in 2006. Morten is a Professor of Systems Biology at the Technical University of Denmark and has received various scientific awards, including the Research excellence prizes from the Hartmann Foundation and the lb Henriksen Foundation. Dr. Sommer holds a M.Sc. in Physics and Biophysics from the University of Copenhagen and a Ph.D. in Biophysics from Harvard University.
Dr. Johansen works as an executive consultant to various life science and venture capital companies. Prior to this, Dr. Johansen has been CEO and Founder of Boston Probes, Inc., Chairman, CEO and Founder of Boston Biosystems Inc., Chairman at Glyco Inc., AdvanDx Inc, 7TM A/S. and Symphogen A/S. He also served as the Executive VIce President of science and technology at Millipore Corporation and President of Millicorp, which is Millipore's venture fund. Dr. Johansen obtained his Ph.D. from the University of Copenhagen and has conducted research within the protein sciences at Harvard Medical School, University of Copenhagen and Carlsberg Research Laboratories.
Jesper Roested is an Investment Director at VF Venture, Vaekstfonden. Previously he has been CEO of 3D, Danish Diagnostic Development A/S and Orbotech Medical Denmark and has had a number of positions in business development in pharma and device companies besides management consulting at McKinsey & Co. Currently Jesper is an active board member of a number of start-up and growth companies in his capacity as venture investor.
Dr. Mahon is an Investment Manager at CAPNOVA, an early stage Venture Fund, and serves on the board of a number of Life Science companies in the CAPNOVA portfolio. Prior to joining CAPNOVA, Dr. Mahon held technical and managerial positions in various Telecommunications Companies in the US, UK and The Netherlands. Dr. Mahon obtained his Ph.D. from the Technical University of Denmark and holds a M.Sc. in Physics from Trinity College, Dublin